UroGen Pharma Ltd

We are a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers.
Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel RTGel™ technology by bringing to patients transformative, nonsurgical approaches to challenging urothelial and specialty cancers—because we believe patients deserve better.

When confronted with challenging conditions in urology, too often there’s no right tool for the job.

That’s why UroGen has developed RTGel, an innovative technology platform designed to work with anatomical complexity—not against it—and facilitate intracavitary treatment of challenging urological conditions.

The RTGel platform has the potential to advance the treatment of urological conditions by: Increasing dwell time and exposure of active drugs, potentially improving the therapeutic effects of existing products; and Potentially increasing the viability of organ-sparing techniques and providing alternatives to radical surgery